Prothena (PRTA) Financials

$6.58 +0.03 (+0.46%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$4.98 -1.60 (-24.30%)

As of 05/23/2025 08:00 PM Eastern

Annual Income Statements for Prothena

This table shows Prothena's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Income / (Loss) Attributable to Common Shareholders	-122	-147	-117
Consolidated Net Income / (Loss)	-122	-147	-117
Net Income / (Loss) Continuing Operations	-122	-147	-117
Total Pre-Tax Income	-129	-160	-126
Total Operating Income	-155	-191	-132
Total Gross Profit	135	91	54
Total Revenue	135	91	54
Operating Revenue	135	91	54
Total Cost of Revenue	0.00	0.00	0.00
Total Operating Expenses	290	282	185
Selling, General & Admin Expense	67	62	50
Research & Development Expense	223	221	136
Total Other Income / (Expense), net	26	31	5.95
Interest Expense	-26	-31	-6.35
Other Income / (Expense), net	-0.19	-0.46	-0.40
Income Tax Expense	-6.62	-13	-8.66
Basic Earnings per Share	($2.27)	($2.76)	($2.47)
Weighted Average Basic Shares Outstanding	53.77M	53.22M	47.37M
Diluted Earnings per Share	($2.27)	($2.76)	($2.47)
Weighted Average Diluted Shares Outstanding	53.77M	53.22M	47.37M
Weighted Average Basic & Diluted Shares Outstanding	53.83M	53.72M	52.56M

This table shows Prothena's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-58	-59	67	-72	-67	22	-55	-47	6.35	-46
Consolidated Net Income / (Loss)	-58	-59	67	-72	-67	22	-55	-47	6.35	-46
Net Income / (Loss) Continuing Operations	-58	-59	67	-72	-67	22	-55	-47	6.35	-46
Total Pre-Tax Income	-60	-60	65	-74	-71	19	-59	-50	3.35	-48
Total Operating Income	-65	-67	58	-82	-79	10	-67	-56	-0.07	-50
Total Gross Profit	2.12	0.97	132	0.05	0.32	85	4.02	2.17	50	1.52
Total Revenue	2.12	0.97	132	0.05	0.32	85	4.02	2.17	50	1.52
Operating Revenue	2.12	0.97	132	0.05	0.32	85	4.02	2.17	50	1.52
Total Operating Expenses	67	67	74	82	79	75	71	58	50	52
Selling, General & Admin Expense	17	17	16	17	17	17	15	14	13	12
Research & Development Expense	50	51	58	64	62	58	56	45	37	40
Total Other Income / (Expense), net	5.40	6.68	6.47	7.09	7.90	8.51	7.60	6.55	3.42	1.92
Interest Expense	-5.39	-6.74	-6.52	-7.17	-8.10	-8.52	-7.70	-6.69	-3.74	-1.91
Other Income / (Expense), net	0.01	-0.07	-0.05	-0.08	-0.21	-0.02	-0.10	-0.14	-0.33	0.00
Income Tax Expense	-1.55	-0.84	-2.04	-2.20	-3.14	-3.09	-4.31	-2.91	-3.00	-2.65
Basic Earnings per Share	($1.07)	($1.10)	$1.24	($1.34)	($1.25)	$0.41	($1.03)	($0.89)	$0.16	($0.97)
Weighted Average Basic Shares Outstanding	53.77M	53.79M	53.77M	53.71M	53.22M	53.56M	53.12M	52.50M	47.37M	46.99M
Diluted Earnings per Share	($1.05)	($1.10)	$1.22	($1.34)	($1.22)	$0.38	($1.03)	($0.89)	$0.16	($0.97)
Weighted Average Diluted Shares Outstanding	53.77M	53.79M	55.04M	53.71M	53.22M	58.00M	53.12M	52.50M	47.37M	46.99M
Weighted Average Basic & Diluted Shares Outstanding	53.83M	53.81M	53.78M	53.77M	53.72M	53.67M	53.54M	52.75M	52.56M	48.38M

This table details how cash moves in and out of Prothena's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Change in Cash & Equivalents	-149	-92	132
Net Cash From Operating Activities	-150	-134	-109
Net Cash From Continuing Operating Activities	-150	-134	-109
Net Income / (Loss) Continuing Operations	-122	-147	-117
Consolidated Net Income / (Loss)	-122	-147	-117
Depreciation Expense	0.89	0.93	0.74
Amortization Expense	2.69	7.48	6.00
Non-Cash Adjustments To Reconcile Net Income	44	35	25
Changes in Operating Assets and Liabilities, net	-75	-30	-24
Net Cash From Investing Activities	-0.30	-2.77	-0.46
Net Cash From Continuing Investing Activities	-0.30	-2.77	-0.46
Purchase of Property, Plant & Equipment	-0.30	-2.81	-0.46
Sale of Property, Plant & Equipment	0.00	0.04	0.00
Net Cash From Financing Activities	1.55	45	241
Net Cash From Continuing Financing Activities	1.55	45	241
Issuance of Common Equity	0.00	21	173
Other Financing Activities, net	1.55	24	69
Cash Income Taxes Paid	3.17	1.55	2.66

This table details how cash moves in and out of Prothena's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-48	-45	16	-72	-52	12	-27	-24	216	-13
Net Cash From Operating Activities	-48	-45	16	-73	-51	9.52	-45	-47	-4.98	-31
Net Cash From Continuing Operating Activities	-48	-45	16	-74	-51	9.52	-45	-47	-4.98	-31
Net Income / (Loss) Continuing Operations	-58	-59	67	-72	-67	22	-55	-47	6.35	-46
Consolidated Net Income / (Loss)	-58	-59	67	-72	-67	22	-55	-47	6.35	-46
Depreciation Expense	0.22	0.23	0.23	0.22	0.28	0.23	0.22	0.20	0.20	0.18
Amortization Expense	0.69	0.67	-	-	2.26	2.08	1.58	1.56	1.53	1.53
Non-Cash Adjustments To Reconcile Net Income	9.87	10	11	12	9.55	9.33	8.50	7.20	5.87	6.42
Changes in Operating Assets and Liabilities, net	-0.60	2.53	-63	-14	4.35	-24	-0.63	-9.56	-19	6.46
Net Cash From Investing Activities	-0.04	-0.01	-0.14	-0.10	-1.51	-0.44	-0.77	-0.05	-0.15	-0.13
Net Cash From Continuing Investing Activities	-0.04	-0.01	-0.14	-0.10	-1.51	-0.44	-0.77	-0.05	-0.15	-0.13
Purchase of Property, Plant & Equipment	-0.04	-0.01	-0.14	-0.10	-1.55	-0.44	-0.77	-0.05	-0.15	-0.13
Net Cash From Financing Activities	-0.06	0.33	0.44	0.84	0.48	2.71	19	23	221	18
Net Cash From Continuing Financing Activities	-0.06	0.33	0.39	0.89	0.48	2.71	19	23	221	18
Other Financing Activities, net	-0.06	0.33	0.39	0.89	0.48	2.71	19	2.56	48	18
Cash Income Taxes Paid	0.76	0.84	1.56	0.02	1.17	0.05	0.33	0.00	0.29	0.75

This table presents Prothena's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Total Assets	547	696	758
Total Current Assets	485	639	719
Cash & Equivalents	471	619	710
Restricted Cash	0.00	1.35	0.00
Accounts Receivable	0.00	5.16	0.00
Prepaid Expenses	14	14	8.69
Plant, Property, & Equipment, net	3.08	3.84	1.73
Total Noncurrent Assets	59	53	37
Noncurrent Deferred & Refundable Income Taxes	43	34	18
Other Noncurrent Operating Assets	15	19	19
Total Liabilities & Shareholders' Equity	547	696	758
Total Liabilities	60	135	136
Total Current Liabilities	49	57	50
Accounts Payable	7.77	25	9.27
Accrued Expenses	13	15	11
Current Deferred Revenue	8.85	0.00	11
Other Current Liabilities	18	17	19
Total Noncurrent Liabilities	12	78	86
Noncurrent Deferred Revenue	3.45	67	85
Other Noncurrent Operating Liabilities	8.23	11	0.55
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	487	561	622
Total Preferred & Common Equity	487	561	622
Total Common Equity	487	561	622
Common Stock	1,589	1,541	1,455
Retained Earnings	-1,102	-980	-833
Other Equity Adjustments	0.00	0.00	0.00

This table presents Prothena's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	595	646	623	747	721	742	554
Total Current Assets	535	586	566	691	677	700	525
Cash & Equivalents	519	564	547	671	659	686	496
Restricted Cash	0.00	0.00	1.35	1.35	1.35	-	-
Accounts Receivable	0.00	0.00	0.00	5.16	0.52	-	-
Prepaid Expenses	16	22	18	13	16	14	29
Plant, Property, & Equipment, net	3.25	3.49	3.67	2.43	2.17	1.92	2.00
Total Noncurrent Assets	57	56	54	54	41	39	28
Noncurrent Deferred & Refundable Income Taxes	41	39	37	30	26	21	15
Other Noncurrent Operating Assets	16	17	17	24	15	18	13
Total Liabilities & Shareholders' Equity	595	646	623	747	721	742	554
Total Liabilities	61	64	121	130	139	134	150
Total Current Liabilities	46	47	43	53	72	49	51
Accounts Payable	10	9.29	14	19	14	13	9.79
Accrued Expenses	10	16	17	18	19	14	12
Current Deferred Revenue	8.83	8.03	0.00	0.32	25	9.32	9.67
Other Current Liabilities	17	14	12	16	14	13	20
Total Noncurrent Liabilities	14	17	78	76	67	85	99
Noncurrent Deferred Revenue	5.59	7.37	67	67	67	85	97
Other Noncurrent Operating Liabilities	8.88	9.54	10	8.92	0.00	0.00	2.20
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	-
Total Equity & Noncontrolling Interests	534	582	502	617	582	607	405
Total Preferred & Common Equity	534	582	502	617	582	607	405
Total Common Equity	534	582	502	617	582	607	405
Common Stock	1,579	1,567	1,555	1,530	1,516	1,487	1,244
Retained Earnings	-1,044	-985	-1,052	-913	-934	-880	-839
Other Equity Adjustments	0.00	0.00	0.00	0.00	0.00	0.00	0.00

This table displays calculated financial ratios and metrics derived from Prothena's official financial filings.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Growth Metrics	-	-	-
Revenue Growth	47.92%	69.50%	-73.13%
EBITDA Growth	17.44%	-46.22%	-259.14%
EBIT Growth	19.19%	-45.12%	-283.58%
NOPAT Growth	19.09%	-45.21%	-237.40%
Net Income Growth	16.81%	-25.72%	-274.62%
EPS Growth	17.75%	-11.74%	-278.99%
Operating Cash Flow Growth	-12.06%	-23.05%	-217.51%
Free Cash Flow Firm Growth	-11.81%	-39.81%	-273.39%
Invested Capital Growth	126.42%	33.44%	21.84%
Revenue Q/Q Growth	1.36%	-35.19%	945.89%
EBITDA Q/Q Growth	7.47%	-73.42%	20.73%
EBIT Q/Q Growth	8.21%	-69.20%	19.86%
NOPAT Q/Q Growth	8.10%	-69.67%	20.06%
Net Income Q/Q Growth	7.22%	-100.85%	25.26%
EPS Q/Q Growth	6.97%	-100.00%	19.02%
Operating Cash Flow Q/Q Growth	2.13%	-52.44%	13.84%
Free Cash Flow Firm Q/Q Growth	2.82%	-42.26%	12.76%
Invested Capital Q/Q Growth	2.90%	-6.90%	2.88%
Profitability Metrics	-	-	-
Gross Margin	100.00%	100.00%	100.00%
EBITDA Margin	-111.84%	-200.37%	-232.28%
Operating Margin	-114.36%	-209.08%	-244.05%
EBIT Margin	-114.49%	-209.58%	-244.79%
Profit (Net Income) Margin	-90.49%	-160.92%	-216.95%
Tax Burden Percent	94.87%	91.62%	93.11%
Interest Burden Percent	83.32%	83.80%	95.19%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%
Return on Equity (ROE)	-23.34%	-24.85%	-21.50%
Cash Return on Invested Capital (CROIC)	-1,174.85%	0.00%	0.00%
Operating Return on Assets (OROA)	-24.89%	-26.33%	-19.30%
Return on Assets (ROA)	-19.67%	-20.22%	-17.11%
Return on Common Equity (ROCE)	-23.34%	-24.85%	-21.50%
Return on Equity Simple (ROE_SIMPLE)	-25.12%	-26.19%	-18.80%
Net Operating Profit after Tax (NOPAT)	-108	-134	-92
NOPAT Margin	-80.05%	-146.36%	-170.84%
Net Nonoperating Expense Percent (NNEP)	-2.59%	-2.00%	-3.86%
Return On Investment Capital (ROIC_SIMPLE)	-22.22%	-23.82%	-14.80%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	49.72%	67.68%	92.57%
R&D to Revenue	164.64%	241.40%	251.48%
Operating Expenses to Revenue	214.36%	309.08%	344.05%
Earnings before Interest and Taxes (EBIT)	-155	-191	-132
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-151	-183	-125
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	1.53	3.47	4.69
Price to Tangible Book Value (P/TBV)	1.53	3.47	4.69
Price to Revenue (P/Rev)	5.51	21.34	54.07
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	17.63	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	2.03	14.56	40.89
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00
Financial Leverage	-1.04	-1.12	-1.19
Leverage Ratio	1.19	1.23	1.26
Compound Leverage Factor	0.99	1.03	1.20
Debt to Total Capital	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00
Altman Z-Score	4.88	6.92	11.88
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	10.01	11.24	14.34
Quick Ratio	9.72	10.97	14.17
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-183	-163	-117
Operating Cash Flow to CapEx	-50,352.35%	-4,828.92%	-23,452.80%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00
Efficiency Ratios	-	-	-
Asset Turnover	0.22	0.13	0.08
Accounts Receivable Turnover	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00
Fixed Asset Turnover	39.08	32.83	28.80
Accounts Payable Turnover	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-
Invested Capital	16	-59	-88
Invested Capital Turnover	-6.25	-1.24	-0.54
Increase / (Decrease) in Invested Capital	74	30	25
Enterprise Value (EV)	274	1,330	2,204
Market Capitalization	745	1,950	2,915
Book Value per Share	$9.05	$10.46	$12.86
Tangible Book Value per Share	$9.05	$10.46	$12.86
Total Capital	487	561	622
Total Debt	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00
Net Debt	-471	-620	-710
Capital Expenditures (CapEx)	0.30	2.77	0.46
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-34	-38	-41
Debt-free Net Working Capital (DFNWC)	437	582	669
Net Working Capital (NWC)	437	582	669
Net Nonoperating Expense (NNE)	14	13	25
Net Nonoperating Obligations (NNO)	-471	-620	-710
Total Depreciation and Amortization (D&A)	3.59	8.41	6.74
Debt-free, Cash-free Net Working Capital to Revenue	-25.51%	-41.36%	-76.90%
Debt-free Net Working Capital to Revenue	323.26%	637.40%	1,240.98%
Net Working Capital to Revenue	323.26%	637.40%	1,240.98%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($2.27)	($2.76)	($2.47)
Adjusted Weighted Average Basic Shares Outstanding	53.77M	53.22M	47.37M
Adjusted Diluted Earnings per Share	($2.27)	($2.76)	($2.47)
Adjusted Weighted Average Diluted Shares Outstanding	53.77M	53.22M	47.37M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	53.83M	53.72M	52.56M
Normalized Net Operating Profit after Tax (NOPAT)	-108	-134	-92
Normalized NOPAT Margin	-80.05%	-146.36%	-170.84%
Pre Tax Income Margin	-95.39%	-175.64%	-233.01%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Prothena's official financial filings.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	571.84%	-98.86%	3,184.75%	-97.69%	-99.37%	5,494.33%	206.33%	88.12%	4,159.64%	-98.91%
EBITDA Growth	16.02%	-621.08%	190.37%	-48.77%	-5,836.52%	125.93%	-55.95%	-50.41%	104.23%	-143.84%
EBIT Growth	17.57%	-746.84%	187.58%	-44.52%	-19,629.32%	120.45%	-54.13%	-48.54%	98.79%	-146.10%
NOPAT Growth	17.34%	-487.93%	229.34%	-44.75%	-40,116.93%	134.07%	-53.91%	-48.44%	99.41%	-132.24%
Net Income Growth	14.11%	-369.32%	222.51%	-54.15%	-1,162.78%	147.87%	-32.37%	-29.14%	119.14%	-141.89%
EPS Growth	13.93%	-389.47%	218.45%	-50.56%	-862.50%	139.18%	-17.05%	-14.10%	138.10%	-145.54%
Operating Cash Flow Growth	6.40%	-574.79%	135.52%	-53.93%	-925.68%	130.54%	-27.41%	-26.84%	77.84%	-127.80%
Free Cash Flow Firm Growth	-41.74%	-387.06%	47.50%	-39.56%	-240.42%	55.54%	-66.00%	-101.02%	-8.70%	-147.87%
Invested Capital Growth	126.42%	127.44%	122.58%	42.29%	33.44%	39.52%	22.38%	24.33%	21.84%	17.01%
Revenue Q/Q Growth	118.87%	-99.27%	263,928.00%	-84.18%	-99.63%	2,011.62%	85.29%	-95.66%	3,190.90%	15.63%
EBITDA Q/Q Growth	2.61%	-212.18%	171.95%	-6.84%	-704.32%	119.45%	-18.45%	-4,219.50%	102.73%	-17.00%
EBIT Q/Q Growth	2.54%	-214.15%	171.47%	-3.66%	-864.79%	115.45%	-17.95%	-14,051.88%	99.21%	-16.48%
NOPAT Q/Q Growth	2.43%	-177.32%	205.51%	-3.84%	-557.93%	125.78%	-18.07%	-28,750.78%	99.61%	-16.49%
Net Income Q/Q Growth	1.77%	-188.21%	192.59%	-7.06%	-408.01%	140.13%	-16.50%	-838.13%	113.87%	-10.96%
EPS Q/Q Growth	4.55%	-190.16%	191.04%	-9.84%	-421.05%	136.89%	-15.73%	-656.25%	116.49%	-10.23%
Operating Cash Flow Q/Q Growth	-5.72%	-383.14%	121.85%	-43.13%	-636.28%	121.18%	5.33%	-853.74%	84.03%	11.62%
Free Cash Flow Firm Q/Q Growth	-2.66%	-220.87%	59.76%	-6.95%	-252.76%	65.41%	-6.96%	-160.87%	53.93%	-29.13%
Invested Capital Q/Q Growth	2.90%	-15.14%	139.14%	22.70%	-6.90%	30.16%	-0.01%	10.85%	2.88%	10.36%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	-3,013.42%	-6,771.86%	44.36%	-162,780.00%	-24,107.91%	14.85%	-1,612.34%	-2,522.22%	2.66%	-3,204.75%
Operating Margin	-3,056.85%	-6,857.01%	44.22%	-163,056.00%	-24,846.52%	12.15%	-1,654.74%	-2,596.82%	-0.14%	-3,317.86%
EBIT Margin	-3,056.43%	-6,863.81%	44.18%	-163,210.00%	-24,911.39%	12.13%	-1,657.15%	-2,603.32%	-0.80%	-3,317.73%
Profit (Net Income) Margin	-2,729.91%	-6,082.58%	50.67%	-144,478.00%	-21,353.16%	25.81%	-1,358.42%	-2,160.63%	12.72%	-3,016.74%
Tax Burden Percent	97.40%	98.60%	103.14%	97.04%	95.55%	116.43%	92.69%	94.15%	189.81%	94.52%
Interest Burden Percent	91.70%	89.87%	111.18%	91.22%	89.71%	182.79%	88.44%	88.15%	-838.35%	96.20%
Effective Tax Rate	0.00%	0.00%	-3.14%	0.00%	0.00%	-16.43%	0.00%	0.00%	-89.81%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-23.34%	-22.90%	-8.75%	-31.07%	-24.85%	-14.33%	-28.49%	-24.38%	-21.50%	-34.96%
Cash Return on Invested Capital (CROIC)	-1,174.85%	-1,244.02%	-902.20%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-664.42%	-1,363.89%	14.05%	-21,346.53%	-3,129.99%	2.63%	-150.36%	-216.14%	-0.06%	-28.81%
Return on Assets (ROA)	-593.44%	-1,208.65%	16.11%	-18,896.53%	-2,682.92%	5.59%	-123.26%	-179.39%	1.00%	-26.19%
Return on Common Equity (ROCE)	-23.34%	-22.90%	-8.75%	-31.07%	-24.85%	-14.33%	-28.49%	-24.38%	-21.50%	-34.96%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-24.67%	-8.75%	-34.32%	0.00%	-11.86%	-24.22%	-20.99%	0.00%	-38.67%
Net Operating Profit after Tax (NOPAT)	-45	-47	60	-57	-55	12	-47	-39	-0.14	-35
NOPAT Margin	-2,139.80%	-4,799.91%	45.61%	-114,139.20%	-17,392.56%	14.14%	-1,158.32%	-1,817.77%	-0.27%	-2,322.50%
Net Nonoperating Expense Percent (NNEP)	-2.30%	-2.09%	1.09%	-2.46%	-1.88%	1.70%	-1.38%	-1.21%	1.01%	-1.92%
Return On Investment Capital (ROIC_SIMPLE)	-9.33%	-	-	-	-9.79%	-	-	-	-0.02%	-
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	793.59%	1,727.84%	12.22%	34,928.00%	5,360.76%	19.61%	361.08%	633.38%	26.29%	790.31%
R&D to Revenue	2,363.26%	5,229.18%	43.56%	128,228.00%	19,585.76%	68.24%	1,393.66%	2,063.44%	73.86%	2,627.55%
Operating Expenses to Revenue	3,156.85%	6,957.01%	55.78%	163,156.00%	24,946.52%	87.85%	1,754.74%	2,696.82%	100.14%	3,417.86%
Earnings before Interest and Taxes (EBIT)	-65	-67	58	-82	-79	10	-67	-56	-0.40	-50
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-64	-66	59	-81	-76	13	-65	-55	1.33	-49
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.53	1.68	1.91	2.65	3.47	4.19	6.19	4.19	4.69	7.03
Price to Tangible Book Value (P/TBV)	1.53	1.68	1.91	2.65	3.47	4.19	6.19	4.19	4.69	7.03
Price to Revenue (P/Rev)	5.51	6.75	5.11	14.89	21.34	18.32	62.50	46.39	54.07	551.99
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	17.63	25.20	30.67	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	2.03	2.85	2.51	8.76	14.56	13.55	51.04	33.90	40.89	455.82
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.04	-1.03	-1.05	-1.11	-1.12	-1.14	-1.18	-1.17	-1.19	-1.22
Leverage Ratio	1.19	1.17	1.17	1.23	1.23	1.27	1.28	1.26	1.26	1.33
Compound Leverage Factor	1.09	1.05	1.31	1.12	1.10	2.33	1.14	1.11	-10.54	1.28
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	5.42	7.25	9.96	4.96	7.46	11.50	14.52	10.61	12.45	10.01
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	10.01	11.52	12.54	13.08	11.24	12.94	9.46	14.33	14.34	10.37
Quick Ratio	9.72	11.19	12.07	12.63	10.97	12.67	9.22	14.04	14.17	9.80
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-120	-117	-36	-90	-85	-24	-69	-65	-25	-54
Operating Cash Flow to CapEx	-111,097.67%	-502,066.67%	11,160.14%	-70,923.30%	-3,294.90%	2,153.17%	-5,827.11%	-98,870.83%	-3,295.36%	-23,974.62%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.22	0.20	0.32	0.13	0.13	0.22	0.09	0.08	0.08	0.01
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	39.08	46.90	76.82	31.90	32.83	63.65	28.59	28.99	28.80	2.62
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	16	15	18	-45	-59	-55	-79	-79	-88	-91
Invested Capital Turnover	-6.25	-6.68	-7.12	-1.44	-1.24	-1.93	-0.64	-0.60	-0.54	-0.05
Increase / (Decrease) in Invested Capital	74	70	97	33	30	36	23	25	25	19
Enterprise Value (EV)	274	380	546	781	1,330	1,911	2,941	1,862	2,204	2,349
Market Capitalization	745	900	1,110	1,329	1,950	2,583	3,602	2,548	2,915	2,845
Book Value per Share	$9.05	$9.94	$10.82	$9.35	$10.46	$11.53	$11.03	$11.56	$12.86	$8.62
Tangible Book Value per Share	$9.05	$9.94	$10.82	$9.35	$10.46	$11.53	$11.03	$11.56	$12.86	$8.62
Total Capital	487	534	582	502	561	617	582	607	622	405
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-471	-519	-564	-548	-620	-672	-660	-686	-710	-496
Capital Expenditures (CapEx)	0.04	0.01	0.14	0.10	1.55	0.44	0.77	0.05	0.15	0.13
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-34	-31	-25	-25	-38	-35	-55	-35	-41	-22
Debt-free Net Working Capital (DFNWC)	437	489	539	523	582	637	606	651	669	474
Net Working Capital (NWC)	437	489	539	523	582	637	606	651	669	474
Net Nonoperating Expense (NNE)	13	12	-6.67	15	13	-9.91	8.04	7.44	-6.49	11
Net Nonoperating Obligations (NNO)	-471	-519	-564	-548	-620	-672	-660	-686	-710	-496
Total Depreciation and Amortization (D&A)	0.91	0.89	0.23	0.22	2.54	2.31	1.80	1.76	1.73	1.71
Debt-free, Cash-free Net Working Capital to Revenue	-25.51%	-23.02%	-11.46%	-28.30%	-41.36%	-24.84%	-95.31%	-63.23%	-76.90%	-420.33%
Debt-free Net Working Capital to Revenue	323.26%	366.38%	248.21%	585.54%	637.40%	452.01%	1,050.77%	1,186.17%	1,240.98%	9,196.04%
Net Working Capital to Revenue	323.26%	366.38%	248.21%	585.54%	637.40%	452.01%	1,050.77%	1,186.17%	1,240.98%	9,196.04%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($1.07)	($1.10)	$1.24	($1.34)	($1.25)	$0.41	($1.03)	($0.89)	$0.16	($0.97)
Adjusted Weighted Average Basic Shares Outstanding	53.77M	53.79M	53.77M	53.71M	53.22M	53.56M	53.12M	52.50M	47.37M	46.99M
Adjusted Diluted Earnings per Share	($1.05)	($1.10)	$1.22	($1.34)	($1.22)	$0.38	($1.03)	($0.89)	$0.16	($0.97)
Adjusted Weighted Average Diluted Shares Outstanding	53.77M	53.79M	55.04M	53.71M	53.22M	58.00M	53.12M	52.50M	47.37M	46.99M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	53.83M	53.81M	53.78M	53.77M	53.72M	53.67M	53.54M	52.75M	52.56M	48.38M
Normalized Net Operating Profit after Tax (NOPAT)	-45	-47	41	-57	-55	7.22	-47	-39	-0.05	-35
Normalized NOPAT Margin	-2,139.80%	-4,799.91%	30.95%	-114,139.20%	-17,392.56%	8.50%	-1,158.32%	-1,817.77%	-0.10%	-2,322.50%
Pre Tax Income Margin	-2,802.68%	-6,168.66%	49.12%	-148,880.00%	-22,347.47%	22.17%	-1,465.56%	-2,294.88%	6.70%	-3,191.63%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Prothena's Financials

When does Prothena's fiscal year end?

According to the most recent income statement we have on file, Prothena's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Prothena's net income changed over the last 2 years?

Prothena's net income appears to be on an upward trend, with a most recent value of -$122.31 million in 2024, rising from -$116.95 million in 2022. The previous period was -$147.03 million in 2023. View Prothena's forecast to see where analysts expect Prothena to go next.

What is Prothena's operating income?

Prothena's total operating income in 2024 was -$154.56 million, based on the following breakdown:

Total Gross Profit: $135.16 million
Total Operating Expenses: $289.72 million

How has Prothena revenue changed over the last 2 years?

Over the last 2 years, Prothena's total revenue changed from $53.91 million in 2022 to $135.16 million in 2024, a change of 150.7%.

How much debt does Prothena have?

Prothena's total liabilities were at $60.18 million at the end of 2024, a 55.4% decrease from 2023, and a 55.7% decrease since 2022.

How much cash does Prothena have?

In the past 2 years, Prothena's cash and equivalents has ranged from $471.39 million in 2024 to $710.41 million in 2022, and is currently $471.39 million as of their latest financial filing in 2024.

How has Prothena's book value per share changed over the last 2 years?

Over the last 2 years, Prothena's book value per share changed from 12.86 in 2022 to 9.05 in 2024, a change of -29.6%.

Related Companies

This page (NASDAQ:PRTA) was last updated on 5/25/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Prothena (PRTA) Financials

Frequently Asked Questions About Prothena's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Prothena (PRTA) Financials

Annual Income Statements for Prothena

Quarterly Income Statements for Prothena

Annual Cash Flow Statements for Prothena

Quarterly Cash Flow Statements for Prothena

Annual Balance Sheets for Prothena

Quarterly Balance Sheets for Prothena

Annual Metrics And Ratios for Prothena

Quarterly Metrics And Ratios for Prothena

Frequently Asked Questions About Prothena's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools